- $7.63bn
- $8.12bn
- $2.50bn
- 78
- 73
- 68
- 84
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,661 | 1,914 | 2,158 | 2,325 | 2,502 |
Cost of Revenue | |||||
Gross Profit | 1,250 | 1,499 | 1,714 | 1,881 | 2,023 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 1,742 | 2,191 | 1,884 | 2,144 | 1,963 |
Operating Profit | -80.5 | -277 | 274 | 181 | 539 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -52 | -250 | 299 | 193 | 554 |
Provision for Income Taxes | |||||
Net Income After Taxes | -52.7 | -256 | 336 | 553 | 454 |
Net Income Before Extraordinary Items | |||||
Net Income | -52.7 | -256 | 336 | 553 | 454 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -52.7 | -256 | 406 | 679 | 560 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.126 | 0.006 | 1.1 | 2.18 | 1.25 |